Supriya Lifescience Q1 FY27: Revenue jumps, margins slip, and the FY27 guidance stays in place

Supriya Lifescience opened FY27 with a sharp jump in revenue, but a clear drop in profitability. In Q1 FY27, revenue from operations grew 31% year-on-year to INR 1,897.5 million. EBITDA declined 8% year-on-year to INR 474.6 million, while PAT declined 31% year-on-year to INR 240.4 million.

The quarter was shaped by two cross-currents. Demand remained supportive, reflected in the strong top-line growth. But management acknowledged a set of temporary disruptions, including higher power and solvent costs and a short operational disruption due to water scarcity at the Lote site. The result was a steep margin compression, with EBITDA margin at 25.0% versus 35.6% in Q1 FY26, and PAT margin at 12.7% versus 24.0%.

What changed in the revenue mix

Exports continued to be the company’s anchor. The presentation showed that exports contributed 81% of Q1 FY27 revenue. The regional mix shifted as well. Asia’s share rose to 39% in Q1 FY27 from 32% in Q1 FY26. Europe’s share reduced to 35% from 41%, while LATAM improved to 20% from 17%. North America remained a small contributor at 3%.

Therapy mix also moved meaningfully. Anesthetics remained the largest therapeutic bucket, but its share fell to 48% in Q1 FY27 from 53% in Q1 FY26. Vitamins increased to 17% from 11%, and anti-asthmatic increased to 9% from 6%. Anti-histamines reduced to 9% from 13%.

While the company did not disclose product-wise revenue in absolute terms, the changes in mix indicate that newer and ramping categories such as vitamins contributed more meaningfully during the quarter.

Margin pressure: what management said and what it implies

Management attributed the weaker profitability to a combination of operational disruption and cost headwinds.

On the cost side, the CFO said margins were impacted by higher solvent and power costs, resulting in an additional operating cost of approximately INR 10.5 crore in the quarter. Management also discussed a power-related retrospective collection linked to solar subsidy, with the CFO stating the retrospective amount was around INR 4.5 crore to INR 5.0 crore. Management indicated this retrospective component was one-time in nature.

On the operational side, management discussed a water scarcity incident that impacted operations for 15 to 20 days. Dr. Saloni Wagh stated that during this period, the company lost production equivalent to INR 30 crore to INR 35 crore. Management said the water issue was resolved after the monsoon improved supply conditions, and they did not expect it to be a recurring issue in Q2.

A key claim from management was that excluding these one-off impacts, margins would have stayed within the guided range. This point matters because the company reiterated FY27 EBITDA margin guidance of 33% to 35% even after reporting a 25% EBITDA margin in Q1.

The near-term question for investors is less about whether the quarter was weak, and more about whether the company can normalize quickly enough to protect full-year guidance. Management’s commentary suggested confidence on two levers: passing through certain cost increases to customers due to purchase order-based pricing, and avoiding any major production shutdown in Q2.

Capacity and execution: balancing debottlenecking with expansion

The company continues to operate a manufacturing base anchored by its Lote facility, with a growing push into forward integration.

In the investor presentation, Supriya Lifescience highlighted a reactor capacity of 932 KLPD and a land area of 35,000 sq. mts, along with five manufacturing blocks. Capacity utilization was stated at 70% in Q1 FY27.

Management also clarified that a previously planned annual maintenance shutdown across Blocks A to D in August would be done in a phased manner instead of a complete shutdown, which they believe will not materially impact Q2 FY27 production.

Beyond Lote, Ambernath is positioned as a finished dosage forms platform. The presentation stated that FDF facilities are commissioned, with manufacturing lines for tablets, capsules, liquids, nasal, inhalation, and injections, and a large volume liquids filling line. Management also said that EU audit dates for Ambernath have been received and the audit is scheduled for the second half of November.

This audit matters because it is a gating milestone for regulated-market momentum from the Ambernath facility. Until audits and filings translate into approvals and commercial orders, the formulation ramp-up will remain largely preparatory.

A third capacity vector is the Isambe or Patalganga land parcel. Management said boundary wall work has started and that Phase 1 capex is around INR 200 crore. They described the first focus as an API block and utility blocks, with formulation blocks to follow later.

Product pipeline: what is visible in FY27

The company outlined a set of product and market initiatives that could define FY27.

Management stated that two new anesthetic liquid inhalation products were launched in Q2 FY27 from the Ambernath facility, with scale-up expected over coming quarters. They also said two ADHD product launches are in the pipeline.

On contrast media, management reiterated that development remains on track and products are expected to be launched in H2 FY27. They also explained why the program was delayed by two quarters: R&D has been fine-tuning technology due to variations in raw material costs and evaluating alternate processes to improve cost competitiveness.

On regulatory progress, the presentation cited 21 USDMFs and 14 CEPs, along with multiple country registrations. In the outlook section, the company stated a plan to file six dossiers in the EU during the current financial year.

In addition, management signaled progress on a CDMO opportunity, stating they are close to signing a term sheet for a large anesthetic CDMO contract, with an expectation to share an update in the next quarter.

Closing takeaways

Q1 FY27 showed that Supriya Lifescience can grow strongly on revenue, but also that earnings can be volatile when operations face short disruptions and input costs spike. The company has been explicit about what hurt margins and quantified key one-offs, which improves the credibility of the explanation.

The more important test now is execution through FY27. Management reiterated the INR 1,000 crore revenue trajectory for FY27 and EBITDA margin guidance of 33% to 35%, while also cautioning that quarterly growth will be non-linear. The near-term watch points are margin normalization, inventory liquidation over the next few quarters, progress on Ambernath audits and dossiers, and whether planned launches like contrast media materialize in H2 FY27 as stated.